New combo attack tested for Tough-to-Treat lung cancer
NCT ID NCT04549428
Summary
This study tested whether adding a single, precise dose of radiation to an immunotherapy drug (atezolizumab) could help control advanced lung cancer that had started to grow again after initial chemotherapy and immunotherapy. It involved 12 adults with stage IV non-small cell lung cancer (NSCLC) who had a limited number of new or growing tumors. The goal was to see if this combination could shrink tumors and delay further cancer progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC STAGE IV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cantonal Hospital of Graubünden (KSGR)
Chur, 7000, Switzerland
-
Geneva University Hospitals (HUG)
Geneva, 1205, Switzerland
-
Oncology Institute of Southern Switzerland
Bellinzona, 6500, Switzerland
Conditions
Explore the condition pages connected to this study.